PT1773451E - Uso de 7-t-butoxiiminometilcamptotecina para o tratamento de neoplasias uterinas - Google Patents
Uso de 7-t-butoxiiminometilcamptotecina para o tratamento de neoplasias uterinas Download PDFInfo
- Publication number
- PT1773451E PT1773451E PT05761294T PT05761294T PT1773451E PT 1773451 E PT1773451 E PT 1773451E PT 05761294 T PT05761294 T PT 05761294T PT 05761294 T PT05761294 T PT 05761294T PT 1773451 E PT1773451 E PT 1773451E
- Authority
- PT
- Portugal
- Prior art keywords
- butoxyiminomethylcamptothecin
- medicament
- use according
- gimatecan
- treatment
- Prior art date
Links
- UIVFUQKYVFCEKJ-OPTOVBNMSA-N gimatecan Chemical compound C1=CC=C2C(\C=N\OC(C)(C)C)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UIVFUQKYVFCEKJ-OPTOVBNMSA-N 0.000 title claims description 14
- 208000002495 Uterine Neoplasms Diseases 0.000 title claims description 6
- 208000025421 tumor of uterus Diseases 0.000 title claims description 4
- 239000003814 drug Substances 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 229950009073 gimatecan Drugs 0.000 description 8
- 206010046766 uterine cancer Diseases 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 210000004696 endometrium Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010061336 Pelvic neoplasm Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000288A ITRM20040288A1 (it) | 2004-06-11 | 2004-06-11 | Uso della 7-t-butossiimminometilcamptotecina per la preparazione di un medicamento per il trattamento delle neoplasie dell'utero. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1773451E true PT1773451E (pt) | 2011-11-02 |
Family
ID=34979678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT05761294T PT1773451E (pt) | 2004-06-11 | 2005-06-08 | Uso de 7-t-butoxiiminometilcamptotecina para o tratamento de neoplasias uterinas |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7700613B2 (enExample) |
| EP (1) | EP1773451B1 (enExample) |
| JP (2) | JP2008501785A (enExample) |
| KR (1) | KR101221640B1 (enExample) |
| CN (2) | CN1953784A (enExample) |
| AR (1) | AR049220A1 (enExample) |
| AT (1) | ATE521351T1 (enExample) |
| AU (1) | AU2005251573B2 (enExample) |
| BR (1) | BRPI0511931A (enExample) |
| CA (1) | CA2565213C (enExample) |
| CY (1) | CY1112032T1 (enExample) |
| DK (1) | DK1773451T3 (enExample) |
| ES (1) | ES2372056T3 (enExample) |
| HK (1) | HK1205951A1 (enExample) |
| HR (1) | HRP20110718T1 (enExample) |
| IT (1) | ITRM20040288A1 (enExample) |
| MX (1) | MXPA06014162A (enExample) |
| PL (1) | PL1773451T3 (enExample) |
| PT (1) | PT1773451E (enExample) |
| RS (1) | RS52038B (enExample) |
| SI (1) | SI1773451T1 (enExample) |
| TW (1) | TWI351283B (enExample) |
| WO (1) | WO2005120643A2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080213385A1 (en) * | 2005-08-10 | 2008-09-04 | Oskar Kalb | Formulations for 7- (T-Butoxy) Iminomethyl Camptothecin |
| AU2008210511A1 (en) * | 2007-02-01 | 2008-08-07 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Pharmaceutical composition comprising a campothecin derivative |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2757514B1 (fr) * | 1996-12-20 | 1999-02-12 | Sod Conseils Rech Applic | Nouveaux analogues de la camptothecine, des procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant |
| DE69635560T2 (de) * | 1995-06-21 | 2006-08-17 | Société de Conseils de Recherches et D'Applications Scientifiques (S.C.R.A.S.) | Camptothecinanaloge, Verfahren zur ihrer Herstellung, ihre Verwendung als Arzneimittel und diese enthaltende pharmazeutische Zusammensetzungen |
| UA57757C2 (uk) * | 1996-12-20 | 2003-07-15 | Сос'Єте Де Консей Де Решерш Е Даплікасьон С'Єнтіфік (С.К.Р.А.С.) | Аналоги камптотецину, спосіб їх отримання (варіанти) і фармацевтична композиція |
| US7105492B2 (en) * | 1999-03-09 | 2006-09-12 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Camptothecin derivatives having antitumor activity |
| DK1044977T3 (da) | 1999-03-09 | 2002-07-08 | Sigma Tau Ind Farmaceuti | Camptothecinderivater med antitumoraktivitet |
| IT1306129B1 (it) * | 1999-04-13 | 2001-05-30 | Sigma Tau Ind Farmaceuti | Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti |
| US6352996B1 (en) * | 1999-08-03 | 2002-03-05 | The Stehlin Foundation For Cancer Research | Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
| WO2003043584A2 (en) | 2001-11-20 | 2003-05-30 | University Of Kentucky Research Foundation | Engineered liposomal particles containing core-loaded pro-drugs for the controlled release of camptothecins |
| WO2004103358A2 (en) * | 2003-05-21 | 2004-12-02 | Novartis Ag | Combination of histone deacetylase inhibitors with chemotherapeutic agents |
-
2004
- 2004-06-11 IT IT000288A patent/ITRM20040288A1/it unknown
-
2005
- 2005-05-19 TW TW094116349A patent/TWI351283B/zh not_active IP Right Cessation
- 2005-06-08 AU AU2005251573A patent/AU2005251573B2/en not_active Ceased
- 2005-06-08 PT PT05761294T patent/PT1773451E/pt unknown
- 2005-06-08 CN CNA2005800157280A patent/CN1953784A/zh active Pending
- 2005-06-08 MX MXPA06014162A patent/MXPA06014162A/es active IP Right Grant
- 2005-06-08 PL PL05761294T patent/PL1773451T3/pl unknown
- 2005-06-08 JP JP2007526712A patent/JP2008501785A/ja not_active Withdrawn
- 2005-06-08 DK DK05761294.7T patent/DK1773451T3/da active
- 2005-06-08 US US11/628,458 patent/US7700613B2/en not_active Expired - Fee Related
- 2005-06-08 CN CN201410616189.7A patent/CN104352496A/zh active Pending
- 2005-06-08 CA CA2565213A patent/CA2565213C/en not_active Expired - Fee Related
- 2005-06-08 ES ES05761294T patent/ES2372056T3/es not_active Expired - Lifetime
- 2005-06-08 SI SI200531393T patent/SI1773451T1/sl unknown
- 2005-06-08 AT AT05761294T patent/ATE521351T1/de active
- 2005-06-08 BR BRPI0511931-6A patent/BRPI0511931A/pt active Search and Examination
- 2005-06-08 WO PCT/IT2005/000320 patent/WO2005120643A2/en not_active Ceased
- 2005-06-08 KR KR1020067027912A patent/KR101221640B1/ko not_active Expired - Fee Related
- 2005-06-08 RS RS20110434A patent/RS52038B/sr unknown
- 2005-06-08 EP EP05761294A patent/EP1773451B1/en not_active Expired - Lifetime
- 2005-06-08 HR HR20110718T patent/HRP20110718T1/hr unknown
- 2005-06-13 AR ARP050102379A patent/AR049220A1/es unknown
-
2011
- 2011-11-14 CY CY20111101092T patent/CY1112032T1/el unknown
-
2014
- 2014-08-15 JP JP2014165542A patent/JP2014231518A/ja active Pending
-
2015
- 2015-07-13 HK HK15106661.8A patent/HK1205951A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TWI351283B (en) | 2011-11-01 |
| CN1953784A (zh) | 2007-04-25 |
| SI1773451T1 (sl) | 2012-01-31 |
| JP2008501785A (ja) | 2008-01-24 |
| ES2372056T3 (es) | 2012-01-13 |
| WO2005120643A8 (en) | 2006-12-14 |
| BRPI0511931A (pt) | 2008-01-22 |
| CA2565213C (en) | 2012-08-07 |
| CA2565213A1 (en) | 2005-12-22 |
| AU2005251573B2 (en) | 2010-04-15 |
| CY1112032T1 (el) | 2015-11-04 |
| ITRM20040288A1 (it) | 2004-09-11 |
| JP2014231518A (ja) | 2014-12-11 |
| AR049220A1 (es) | 2006-07-05 |
| WO2005120643A3 (en) | 2006-03-30 |
| CN104352496A (zh) | 2015-02-18 |
| AU2005251573A1 (en) | 2005-12-22 |
| US7700613B2 (en) | 2010-04-20 |
| DK1773451T3 (da) | 2011-11-28 |
| KR101221640B1 (ko) | 2013-01-14 |
| WO2005120643A2 (en) | 2005-12-22 |
| MXPA06014162A (es) | 2007-03-07 |
| EP1773451A2 (en) | 2007-04-18 |
| EP1773451B1 (en) | 2011-08-24 |
| US20080020030A1 (en) | 2008-01-24 |
| RS52038B (sr) | 2012-04-30 |
| HRP20110718T1 (hr) | 2011-12-31 |
| KR20070030246A (ko) | 2007-03-15 |
| TW200605891A (en) | 2006-02-16 |
| ATE521351T1 (de) | 2011-09-15 |
| HK1205951A1 (en) | 2015-12-31 |
| PL1773451T3 (pl) | 2012-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Petrioli et al. | Comparison between a cisplatin‐containing regimen and a carboplatin‐containing regimen for recurrent or metastatic bladder cancer patients: A randomized phase II study | |
| ES2705016T3 (es) | Derivado de rapamicina para el tratamiento de cáncer de pulmón | |
| US12257237B2 (en) | Tinostamustine for use in treating sarcoma | |
| EP3503923B1 (en) | Combination therapies for the treatment of hepatocellular carcinoma | |
| TW201919615A (zh) | 用於治療tnbc的化合物 | |
| JP2022534118A5 (enExample) | ||
| CN111728974B (zh) | 西奥罗尼用于小细胞肺癌的治疗 | |
| JP2014231518A (ja) | 子宮腫瘍の治療用医薬の調製のための７−ｔ−ブトキシイミノメチルカンプトテシンの使用 | |
| EP1812018A1 (en) | Treatment and prevention of multi-drug resistance | |
| HK1104002A (en) | Use of 7-t-butoxyiminomethylcamptothecin for treating uterine neoplasms | |
| CN110339195A (zh) | 用于治疗胆管癌的喹啉衍生物 | |
| TW202532086A (zh) | 治療對卡介苗療法無反應之高風險非肌肉侵襲性膀胱癌之方法 | |
| HK40111558A (en) | Pharmaceutical composition including phthalazinone derivative for co-administration with anticancer drug | |
| RU2024109560A (ru) | Фармацевтическая композиция и ее применение |